Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 238 results
Author
Title
[
Type
]
Year
Filters:
First Letter Of Last Name
is
S
[Clear All Filters]
Journal Article
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Poppers DM
,
Scherl EJ
. 2008.
Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.
.
Inflamm Bowel Dis. 14(1):106-13.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shen T-CDavid
,
Lebwohl B
,
Verma H
,
Kumta N
,
Tennyson C
,
Lewis S
,
Scherl E
,
Swaminath A
,
Capiak KM
,
DiGiacomo D
et al.
. 2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.
.
J Clin Neuromuscul Dis. 13(3):137-45.
Shen T-CDavid
,
Lebwohl B
,
Verma H
,
Kumta N
,
Tennyson C
,
Lewis S
,
Scherl E
,
Swaminath A
,
Capiak KM
,
DiGiacomo D
et al.
. 2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.
.
J Clin Neuromuscul Dis. 13(3):137-45.
Shen T-CDavid
,
Lebwohl B
,
Verma H
,
Kumta N
,
Tennyson C
,
Lewis S
,
Scherl E
,
Swaminath A
,
Capiak KM
,
DiGiacomo D
et al.
. 2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.
.
J Clin Neuromuscul Dis. 13(3):137-45.
Stathopoulos C
,
Li T
,
Longman R
,
Vothknecht UC
,
Becker HD
,
Ibba M
,
Söll D
. 2000.
One polypeptide with two aminoacyl-tRNA synthetase activities.
.
Science. 287(5452):479-82.
Stathopoulos C
,
Li T
,
Longman R
,
Vothknecht UC
,
Becker HD
,
Ibba M
,
Söll D
. 2000.
One polypeptide with two aminoacyl-tRNA synthetase activities.
.
Science. 287(5452):479-82.
Kivolowitz C
,
Abdulhamid A
,
Victorio D
,
Castellanos J
,
Simpson K
,
Scherl E
,
Longman R
. 2016.
O-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.
.
Inflamm Bowel Dis. 22 Suppl 1:S3.
Kivolowitz C
,
Abdulhamid A
,
Victorio D
,
Castellanos J
,
Simpson K
,
Scherl E
,
Longman R
. 2016.
O-006 Expansion of Immunologically-Relevant E. Coli in the Intestinal Microbiota of Patients with IBD-Associated Spondyloarthritis Promotes Mucosal RORgt-Dependent Immunity.
.
Inflamm Bowel Dis. 22 Suppl 1:S3.
Lukin DJ
,
Funez-dePagnier G
,
Lima S
,
Lai D
,
Duenas-Bianchi L
,
Ahmed W
,
Jacob V
,
Battat R
,
Scherl E
,
Longman RS
. 2021.
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.
.
Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.
Dogan B
,
Scherl E
,
Bosworth B
,
Yantiss R
,
Altier C
,
McDonough PL
,
Jiang Z-D
,
Dupont HL
,
Garneau P
,
Harel J
et al.
. 2013.
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.
.
Inflamm Bowel Dis. 19(1):141-50.
Dogan B
,
Scherl E
,
Bosworth B
,
Yantiss R
,
Altier C
,
McDonough PL
,
Jiang Z-D
,
Dupont HL
,
Garneau P
,
Harel J
et al.
. 2013.
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.
.
Inflamm Bowel Dis. 19(1):141-50.
Castellanos JG
,
Woo V
,
Viladomiu M
,
Putzel G
,
Lima S
,
Diehl GE
,
Marderstein AR
,
Gandara J
,
Perez AR
,
Withers DR
et al.
. 2018.
Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.
.
Immunity. 49(6):1077-1089.e5.
Castellanos JG
,
Woo V
,
Viladomiu M
,
Putzel G
,
Lima S
,
Diehl GE
,
Marderstein AR
,
Gandara J
,
Perez AR
,
Withers DR
et al.
. 2018.
Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.
.
Immunity. 49(6):1077-1089.e5.
Diehl GE
,
Longman RS
,
Zhang J-X
,
Breart B
,
Galan C
,
Cuesta A
,
Schwab SR
,
Littman DR
. 2013.
Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.
.
Nature. 494(7435):116-20.
Stathopoulos C
,
Jacquin-Becker C
,
Becker HD
,
Li T
,
Ambrogelly A
,
Longman R
,
Söll D
. 2001.
Methanococcus jannaschii prolyl-cysteinyl-tRNA synthetase possesses overlapping amino acid binding sites.
.
Biochemistry. 40(1):46-52.
« first
‹ previous
1
2
3
4
(current)
5
6
7
8
9
next ›
last »